Product Name

Wegovy, 2.4 Mg, Pre-Filled Pen - 1 Pen

Brand

Novo Nordisk

Main Category

Weight Loss Medications / Anti-Obesity Drugs

Description

• Wegovy contains semaglutide, a synthetic analog of the human GLP-1 hormone.
• Produced using recombinant DNA technology in yeast cells.
• Targets brain areas responsible for appetite regulation, reducing calorie intake.
• Available as a weekly subcutaneous injection using prefilled pens.

Wegovy Indication

• Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with:
  • An initial Body Mass Index (BMI) of ≥30 kg/m² (obesity)
  • A BMI of ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbidity (such as prediabetes, type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).

Benefits

• Helps with significant weight loss when combined with a low-calorie diet and increased physical activity.
• Reduces appetite and slows stomach emptying, promoting satiety.
• Effective for patients with weight-related health conditions like diabetes and cardiovascular disease.

Instructions For Use

• Inject subcutaneously once weekly in the abdomen, thigh, or upper arm.
• Can be taken at any time of the day, with or without food.
• Start with 0.25 mg weekly, increasing gradually based on the following schedule:
  • Week 1 - 4: 0.25 mg
  • Week 5 - 8: 0.5 mg
  • Week 9 - 12: 1 mg
  • Week 13 - 16: 1.7 mg
  • From Week 17 onward: 2.4 mg (maintenance dose)
  • Rotate injection sites to avoid skin irritation.

What To Do If You Miss a Dose

• If a dose is missed, administer it within 5 days of the scheduled time.
• If more than 5 days have passed, skip the dose and resume the regular schedule.
• The injection day can be changed if there is at least 72 hours between doses.

Important Information

• Not recommended for patients with severe renal impairment (eGFR <30 mL/min/1.73m²) or end-stage renal disease.
• Not recommended for patients with severe hepatic impairment; use cautiously in patients with mild to moderate hepatic impairment.
• May cause gastrointestinal adverse reactions that can lead to dehydration. Patients should take precautions to avoid fluid depletion.
• Acute pancreatitis has been observed with GLP-1 receptor agonists. Discontinue if pancreatitis is suspected.
• Should not be used as a substitute for insulin in patients with type 2 diabetes.
• Not to be used in combination with other GLP-1 receptor agonist products.
• May increase the risk of hypoglycemia when used with insulin or sulfonylureas in patients with type 2 diabetes.
• Not recommended during pregnancy or breastfeeding.
• Women of childbearing potential should use contraception during treatment.
• Should be discontinued at least 2 months before a planned pregnancy.
• Not recommended for patients under 18 years of age.

Ingredients

• Active Ingredient: Semaglutide, a GLP-1 analog produced via recombinant DNA technology in yeast (Saccharomyces cerevisiae).
• Available concentrations: (0.25 mg), (0.5 mg), (1 mg), (1.7 mg), (2.4 mg).
• Inactive ingredients: Disodium phosphate dihydrate, sodium chloride, hydrochloric acid, sodium hydroxide, Propylene glycol, phenol, water for injection.

Product Details

• Form: Injectable solution in prefilled pens.
• Multi-dose FlexTouch pens containing four doses.
• The solution is clear and colorless.

Storage Instructions

• Store in the refrigerator at 2–8°C.
• Do not freeze under any circumstances.
• Single-use pens may be stored at room temperature (below 30°C) for up to 28 days.
• FlexTouch pens may be used for up to 6 weeks after first use, either at room temperature or in the refrigerator.

For More Information About Semaglutide

• Ask your physician or pharmacist
• Visit SFDA website
• Visit Medscape at Information About Semaglutide
• Visit Drugs.com at Information About Semaglutide
• Visit DrugBank.com at Information About Semaglutide